Renal denervation: What happened, and why?

Area of Science:

• Cardiovascular medicine
• Interventional nephrology

Background:

• Resistant hypertension poses a significant clinical challenge.
• Renal denervation emerged as a potential therapeutic option for managing resistant hypertension.
• Initial studies suggested favorable outcomes for renal denervation.

Purpose of the Study:

• To evaluate the efficacy and safety of renal denervation in patients with resistant hypertension.
• To assess the primary end points of the SYMPLICITY HTN-3 trial.

Main Methods:

• The SYMPLICITY HTN-3 trial was the largest randomized controlled trial to date for renal denervation.
• The study involved patients with treatment-resistant hypertension undergoing the procedure.

Main Results:

• Renal denervation did not meet its primary efficacy end points in the SYMPLICITY HTN-3 trial.
• The procedure failed to demonstrate a statistically significant reduction in blood pressure compared to a sham procedure.

Conclusions:

• The SYMPLICITY HTN-3 trial results cast doubt on the efficacy of renal denervation for resistant hypertension.
• Further investigation into newer technologies and patient selection may be necessary to determine the future role of renal denervation.